| human | Q5 |
| P735 | given name | Björn | Q8851571 |
| Björn | Q8851571 | ||
| P106 | occupation | researcher | Q1650915 |
| Q82746152 | A method to include the environmental hazard in drug prescribing |
| Q56828640 | A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists |
| Q50926069 | Adherence to guidelines for drug treatment of asthma in children: potential for improvement in Swedish primary care. |
| Q47156289 | Antibiotic use and bacterial complications following upper respiratory tract infections: a population-based study. |
| Q38742284 | Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease |
| Q80603401 | Attitudes to feedback with drug utilisation 90% (DU90%) profiles among prescribers in Rijeka, Croatia |
| Q60046512 | Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets |
| Q47906571 | Cardiovascular outcome in treatment-resistant hypertension: results from the Swedish Primary Care Cardiovascular Database (SPCCD). |
| Q94958022 | Challenges facing drug utilization research in the Latin American region |
| Q44560607 | Changes in the utilization of venlafaxine after the introduction of generics in Sweden |
| Q37847158 | Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs |
| Q39805925 | Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications |
| Q40267269 | Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation |
| Q90047481 | Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding |
| Q35948865 | Concomitant use of two or more antipsychotic drugs is common in Sweden |
| Q92262211 | Current antihypertensive drug therapy in 12,436 Swedish patients, 90 years and above, in relation to sex and comorbidity |
| Q57024257 | Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System |
| Q36821784 | Differences in drug utilisation between men and women: a cross-sectional analysis of all dispensed drugs in Sweden |
| Q48200779 | Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies |
| Q56828318 | Diffusion of interferon beta in Iran and its utilization in Tehran |
| Q57033763 | Discontinuation of antidepressants in suicides |
| Q80778863 | Dispensed volumes of anti-asthmatic drugs related to the prevalence of asthma and COPD in Sweden |
| Q48211674 | Drug adherence in treatment resistant and in controlled hypertension-Results from the Swedish Primary Care Cardiovascular Database (SPCCD). |
| Q43891950 | Drug treatment in patients with newly diagnosed unprovoked seizures/epilepsy |
| Q47343010 | Drug treatment of hypertension in Sweden in relation to sex, age, and comorbidity. |
| Q35547991 | Drug utilisation 90% profiles--a useful tool for quality assessment of prescribing in primary health care in Stockholm |
| Q98157575 | Drug-disease interactions in Swedish senior primary care patients were dominated by non-steroid anti-inflammatory drugs and hypertension - a population-based registry study |
| Q39300348 | Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis |
| Q89585336 | Electronic assessment of cardiovascular potentially inappropriate medications in an administrative population database |
| Q92681649 | Eliminated patient fee and changes in dispensing patterns of asthma medication in children-An interrupted time series analysis |
| Q56828606 | Enhancing the rational use of new medicines across European health care systems |
| Q84357748 | European countries with small populations can obtain low prices for drugs: Lithuania as a case history |
| Q34572340 | Extraction of electronic health record data in a hospital setting: comparison of automatic and semi-automatic methods using anti-TNF therapy as model |
| Q40140300 | Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs. |
| Q57267088 | Factors associated with concordance between parental-reported use and dispensed asthma drugs in adolescents: findings from the BAMSE birth cohort |
| Q44785732 | Factors associated with pregabalin dispensing at higher than the approved maximum dose |
| Q87412137 | Family history of cardiovascular disease and influence on statin therapy persistence |
| Q93152732 | Financial incentives linked to quality improvement projects in Swedish primary care: a model for improving quality of care |
| Q44662160 | Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care. |
| Q33579584 | Forecasting drug utilization and expenditure in a metropolitan health region |
| Q94559290 | Forecasting drug utilization and expenditure: ten years of experience in Stockholm |
| Q86231940 | Gender differences in antihypertensive drug treatment: results from the Swedish Primary Care Cardiovascular Database (SPCCD) |
| Q39391967 | HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY. |
| Q47150301 | Health care use, drug treatment and comorbidity in patients with schizophrenia or non-affective psychosis in Sweden: a cross-sectional study |
| Q37118397 | Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease. |
| Q38786308 | Healthcare resource use, comorbidity, treatment and clinical outcomes for patients with primary intracranial tumors: a Swedish population-based register study. |
| Q38808074 | High adherence to the 'Wise List' treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines |
| Q34834870 | High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden - a challenge for public health |
| Q40806829 | How to best assess quality of drug treatment in patients with heart failure |
| Q88993735 | Immunosuppressants in Brazil: underlying drivers of spending trends, 2010-2015 |
| Q39940166 | Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future |
| Q42945097 | Impact of restricted amoxicillin/clavulanic acid use on Escherichia coli resistance--antibiotic DU90% profiles with bacterial resistance rates: a visual presentation |
| Q57823146 | Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants |
| Q53793973 | Improved treatment and control of hypertension in Swedish primary care: results from the Swedish primary care cardiovascular database. |
| Q33957060 | Individual data about dispensed drug prescriptions--quality indicator for primary health care |
| Q40208462 | Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence |
| Q37625054 | Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment |
| Q43102979 | Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries |
| Q43178513 | Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications |
| Q93176431 | Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk |
| Q43243680 | Lower and lower cholesterol targets increase adverse effects |
| Q45893590 | Management of antihypertensive drugs in three European countries |
| Q92777683 | Medication persistence to antihypertensive drug treatment - a cross-sectional study of attitudes towards hypertension and medication in persistent and non-persistent patients |
| Q40208476 | Medicine use and disease control among adolescents with asthma |
| Q42607289 | Most common diseases diagnosed in primary care in Stockholm, Sweden, in 2011. |
| Q37445843 | Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance |
| Q21129272 | Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications |
| Q33560299 | Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions |
| Q40791111 | Neighborhood Socioeconomic Characteristics and Utilization of ADHD Medication in Schoolchildren: A Population Multilevel Study in Stockholm County |
| Q38918730 | Non-steroidal anti-inflammatory drugs and blood pressure control in patients treated for hypertension: results from the Swedish primary care cardiovascular database |
| Q59318394 | O01 - Validation of asthma and eczema in population-based Swedish health registers |
| Q37328828 | Persistence to antihypertensive drug classes: A cohort study using the Swedish Primary Care Cardiovascular Database (SPCCD). |
| Q87099645 | Persistence to antihypertensive drug treatment in Swedish primary healthcare |
| Q47612186 | Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study. |
| Q35155250 | Policies to enhance prescribing efficiency in europe: findings and future implications |
| Q37639328 | Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction |
| Q40542860 | Prevalence and recognition of chronic kidney disease in Stockholm healthcare |
| Q57452780 | Prevalence of renally inappropriate medicines in older people with renal impairment - A cross-sectional register-based study in a large primary care population |
| Q39319513 | Prevalence of treatment-resistant hypertension and important associated factors-results from the Swedish Primary Care Cardiovascular Database |
| Q28544621 | Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe |
| Q44695835 | Quality indicators as a tool in improving the introduction of new medicines |
| Q44055468 | Quality of non-steroidal anti-inflammatory drug prescribing in Croatia (Rijeka) and Sweden (Stockholm). |
| Q93185269 | Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study |
| Q37194749 | Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. |
| Q39938950 | Regional variation and adherence to guidelines for drug treatment of asthma |
| Q30696094 | Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system |
| Q45350454 | Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region |
| Q43274723 | SBU should investigate what is an evidence-based and cost-effective use of statins |
| Q45918326 | Secondary prevention in a large stroke population: a study of patients' purchase of recommended drugs. |
| Q38619544 | Sex and Gender Differences in Thromboprophylactic Treatment of Patients With Atrial Fibrillation After the Introduction of Non-Vitamin K Oral Anticoagulants |
| Q51505075 | Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment. |
| Q91604225 | Sibship and dispensing patterns of asthma medication in young children-a population-based study |
| Q38859013 | Sociodemographic factors are associated with utilisation of statins after ischaemic stroke/TIA. |
| Q86968738 | Socioeconomic status and the quality of prescribing asthma drugs in Sweden |
| Q39942163 | Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences |
| Q46783354 | Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects |
| Q38972335 | Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. |
| Q94555878 | Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort |
| Q47645689 | The Early Awareness and Alert System in Sweden: History and Current Status |
| Q38817217 | The First Decade with the Swedish Prescribed Drug Register - A Systematic Review of the Output in the Scientific Literature |
| Q37644540 | The Nordic countries as a cohort for pharmacoepidemiological research |
| Q36482888 | The Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativeness |
| Q40128700 | The Swedish Primary Care Cardiovascular Database (SPCCD): 74 751 hypertensive primary care patients. |
| Q90732303 | The benzodiazepine nation of Croatia: an observational, comparative study of psychotropic drug utilization between Croatia and Sweden 2014-2015 |
| Q50048951 | The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations. |
| Q30621154 | The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden |
| Q45890951 | The establishment and expansion of an innovative centre for rational pharmacotherapy--determinants and challenges |
| Q39422831 | The intriguing future of pharmacoepidemiology |
| Q55496629 | The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil. |
| Q38404794 | The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months |
| Q56828572 | The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm |
| Q36773079 | Time trends in statin utilisation and coronary mortality in Western European countries |
| Q28535299 | Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe |
| Q38039947 | Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden |
| Q36339862 | Trends in medicines procurement by the Brazilian federal government from 2006 to 2013. |
| Q40928690 | Unexplained acute chest pain in young adults: disease patterns and medication use 25 years later |
| Q46099072 | Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs |
| Q35113912 | Usage, risk, and benefit of weight-loss drugs in primary care |
| Q33664087 | Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe? |
| Q33360298 | Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines |
| Q39963170 | Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden |
| Q50088178 | Utilization of Antiepileptic Medicines in Swedish Children and Adolescents with Different Diagnoses |
| Q48070303 | Utilization of triptans in Sweden; analyses of over the counter and prescription sales |
| Q39404480 | Validation of asthma and eczema in population-based Swedish drug and patient registers |
| Q91308513 | Valproic acid utilization among girls and women in Stockholm: Impact of regulatory restrictions |
| Q56828611 | [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment] |
| Q84138057 | [Anti-obesity agents do not seem to have any beneficial effects. Health centers prescribe preparations haphazardly, according to a medical records study] |
| Q82650424 | [Big gender differences in drug utilization. The underlying disease is an insufficient explanation according to a systematic analysis] |
| Q84194590 | [Follow up studies as a condition for drug subsidizing] |
| Q84189179 | [Fully possible to reduce the costs of hypertension treatment] |
| Q95614959 | [More with atrial fibrillation, anticoagulants since the coming of NOAK ] |
| Q56828349 | [Quality indicators for drug prescribing--the situation in Sweden] |
| Q56828353 | [Quality indicators for drug utilization--new European recommendations] |
| Q82688150 | [Quality reports reduce drug costs in primary health care. Stockholm County Council a model for decentralized expenditure responsibility] |
| Q82688143 | [Rational drug prescription: a question of knowledge and direction. Qualitative study at ten community health centers in the county of Stockholm] |
| Q56828593 | [Rational introduction to new drugs requires both a health care and a community perspective] |
| Q82229819 | [Say no to the extremes in the debate on lipid reduction] |
| Q83789392 | [Visions are good but the guidelines require evidence] |
Search more.